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ABSTRACT
Background Invasive non- typhoidal Salmonella (iNTS) is 
one of the leading causes of bacteraemia in sub- Saharan 
Africa. We aimed to provide a better understanding of 
the genetic characteristics and transmission patterns 
associated with multi- drug resistant (MDR) iNTS serovars 
across the continent.
Methods A total of 166 iNTS isolates collected from 
a multi- centre surveillance in 10 African countries 
(2010–2014) and a fever study in Ghana (2007–2009) 
were genome sequenced to investigate the geographical 
distribution, antimicrobial genetic determinants and 
population structure of iNTS serotypes–genotypes. 
Phylogenetic analyses were conducted in the context of the 
existing genomic frameworks for various iNTS serovars. 
Population- based incidence of MDR- iNTS disease was 
estimated in each study site.
Results Salmonella Typhimurium sequence- type (ST) 313 
and Salmonella Enteritidis ST11 were predominant, and both 
exhibited high frequencies of MDR; Salmonella Dublin ST10 
was identified in West Africa only. Mutations in the gyrA gene 
(fluoroquinolone resistance) were identified in S. Enteritidis 
and S. Typhimurium in Ghana; an ST313 isolate carrying 
blaCTX- M-15 was found in Kenya. International transmission 
of MDR ST313 (lineage II) and MDR ST11 (West African 
clade) was observed between Ghana and neighbouring 
West African countries. The incidence of MDR- iNTS disease 
exceeded 100/100 000 person- years- of- observation in 
children aged <5 years in several West African countries.
Conclusions We identified the circulation of multiple MDR 
iNTS serovar STs in the sampled sub- Saharan African 
countries. Investment in the development and deployment 
of iNTS vaccines coupled with intensified antimicrobial 
resistance surveillance are essential to limit the impact of 
these pathogens in Africa.
BACKGROUND
The non- typhoidal members of Salmonella 
enterica are archetypal zoonotic pathogens typi-
cally associated with self- limiting diarrhoea in 
humans. However, certain non- typhoidal Salmo-
nella serovars are also a recognised cause of 
invasive disease in specific geographical regions. 
Invasive non- typhoidal Salmonella (iNTS) is 
Key questions
What is already known?
 ► Invasive non- typhoidal Salmonella (iNTS) disease is 
an emerging pathogen in sub- Saharan Africa.
 ► iNTS is now a leading cause of bacteraemia in sub- 
Saharan Africa.
 ► The disease is associated with specific sequence 
types of S. Enteritidis and S. Typhimurium.
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most commonly observed in infants and young adults with 
HIV, malaria and malnutrition.1 Annually, there are an esti-
mated 3.4 million cases of iNTS globally, 20% of which are 
fatal.2 3 The vast majority of iNTS disease is reported in sub- 
Saharan Africa, where annual incidence rates of 175–388 
cases per 100 000 person- years and case fatality rates as high 
as 25% have been reported in young children.4–6 A recent 
multi- centre study across 10 countries in sub- Saharan Africa 
identified iNTS as a major cause of bacteraemia in febrile 
patients, with incidence rates exceeding 100 cases per 100 
000 person- years recorded in multiple sampling locations.7
Various Salmonella serovars have been associated with 
iNTS disease, including S. Isangi,8 S. Concord,9 S. Stan-
leyville and S. Dublin.10 However, the majority of iNTS 
infections in sub- Saharan Africa can be attributed to S. 
Typhimurium and S. Enteritidis.11 12 Salmonella Typh-
imurium iNTS in sub- Saharan Africa is largely asso-
ciated with a multi- drug resistant (MDR; resistant to 
ampicillin, chloramphenicol and trimethoprim–sulfa-
methoxazole) variant of ST313, which comprised two 
major lineages (I and II).11 Salmonella Enteritidis account 
for approximately one- third of the iNTS cases reported 
in sub- Saharan Africa and are primarily associated with 
genotype ST11. There are three major clades of S. Enter-
itidis ST11 (Global epidemic, West African and Central/
East African clades) co- circulating in this region, in which 
MDR phenotypes are common.13
Ampicillin, chloramphenicol and trimethoprim–sulfa-
methoxazole (co- trimoxazole) have traditionally served as 
first- line treatment for iNTS and typhoid fever in Africa.14 
The widespread use of these antimicrobials likely led to the 
emergence and spread of MDR iNTS organisms. Several 
sub- Saharan African countries have reported MDR iNTS, 
including Malawi,15–17 Kenya,18–20 Ghana,21 Gambia,5 
Democratic Republic of the Congo (DRC),22 Mozam-
bique,23 24 Tanzania,25 Burkina Faso,7 Guinea- Bissau7 and 
Nigeria.26 Consequently, alternative treatments, such as 
ciprofloxacin, azithromycin and ceftriaxone, are used 
increasingly to manage bloodstream infections. However, 
these drugs may be unavailable or costly, and resistance is 
emerging to these antimicrobial agents.17 Concerningly, 
extensively drug- resistant (XDR) (MDR plus resistance to 
fluoroquinolones and third- generation cephalosporins) 
S. Typhimurium ST313 organisms have been reported 
in Kenya,14 27 Malawi28 and DRC.29 These new resistance 
phenotypes pose a significant challenge for the control 
of iNTS disease.14
Here, we subjected a contemporaneous collection of iNTS 
organisms from multiple sites in sub- Saharan Africa to whole 
genome sequencing to investigate the phylogenetic distribu-
tion of these organisms and their corresponding sequence 
types (STs) and antimicrobial resistance (AMR) determi-
nants. We also estimated the incidence rates of MDR iNTS 
disease in the sampling locations and performed phyloge-
netic analyses of S. Typhimurium ST313 and S. Enteritidis 
ST11 in a global context.
METHODS
Ethics approval and consent to participate
This research was conducted under the ethical prin-
ciples of the Declaration of Helsinki. The IVI Institu-
tional Review Board (IRB), the national ethical review 
committees in each participating country, and local 
research ethics committees approved the study protocol. 
All eligible patients meeting the study inclusion criteria 
were provided with a detailed explanation of the study 
purpose, and written informed consent was obtained 
prior to study enrolment. For children, written informed 
consent was obtained from parent or guardian.30
Study design and inclusion criteria
The majority of iNTS isolates (117/166) in this study 
originated from the Typhoid Fever Surveillance in Africa 
Program (TSAP),30 conducted in 13 sites in 10 countries 
between 2010 and 2014. Febrile patients from all age 
groups (except in Ghana, where only children aged <15 
years were enrolled) with a tympanic or axillary temper-
ature of ≥38.0℃ or ≥37.5℃, respectively, living in a 
defined study catchment area were eligible for recruit-
ment. For inpatients, reported fever within 72 hours 
of admission was also necessary for inclusion. Written 
informed consent/assent was obtained. Clinical assess-
ments of patients included history of illness, physical 
examination and clinical appraisal. Blood samples (5–10 
mL for adults; 1–3 mL for children) were collected for 
microbiological testing and diagnosis. An additional 49 
iNTS isolates were obtained from a febrile surveillance 
study conducted at the Presbyterian Hospital of Agogo in 
Ghana, between 2007 and 2009.31
Patient and public involvement statement
This TSAP study was performed under a single protocol 
with some site- specific and country- specific details; these 
details were developed with the study sites and local 
patient groups and communities attending the health-
care facilities. These data were essential for establishing 
the demographic framework of the sites and under-
standing how patients accessed healthcare and disease 
diagnosis. Therefore, these patient/community groups 
Key questions
What are the new findings?
 ► iNTS disease is widespread across the sampled locations.
 ► Salmonella Typhimurium sequence- type (ST) 313 and Salmonella 
Enteritidis ST11 are the predominant pathogens.
 ► There is a high frequency of multi- drug resistant (MDR) phenotypes.
 ► The incidence of MDR- iNTS disease exceeded 100/100 000 
person- years- of- observation in children aged <5 years in several 
West African countries.
What do the new findings imply?
 ► Sustained disease surveillance of MDR- iNTS organisms is essential.
 ► There is a need for acceleration of iNTS vaccines.
 ► We need a better understanding of the disease reservoir and 
human- to- human transmission.
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% of total number 








% of total number 




Typhimurium 7 58 313 6 50
  19 1 8
Enteritidis 4 33 11 4 33
Dublin 1 8 10 1 8
Ghana (133) Typhimurium 92 69 313 90 68
  19 2 2
Enteritidis 20 15 11 18 14
  183 1 1
  2107 1 1
Dublin 17 13 10 17 13
Muenster 1 1 321 1 1
Poona 1 1 308 1 1
Stanleyville 1 1 339 1 1
Virchow 1 1 359 1 1
Guinea- 
Bissau (9)
Typhimurium 5 56 313 2 22
  19 3 33
Enteritidis 1 11 11 *1 11
Choleraesuis 3 33 145 3 33
Kenya (1) Typhimurium 1 100 313 1 100
Madagascar 
(4)
Typhimurium 1 25 19 *1 25
Enteritidis 3 75 11 ‡3 75
Senegal (2) Typhimurium 1 50 19 *1 50
Enteritidis 1 50 11 *1 50
South Africa 
(1)
Enteritidis 1 100 11 *1 100
Tanzania (4) Typhimurium 3 75 19 3 75








% of total number 




Number of iNTS 
per genotype (f)
% of total number of 
iNTS in all 8 countries 
(f)/(d)
  Typhimurium 110 66 ST313 99 60
    ST19 11 7
  Enteritidis 30 18 ST11 28 17
    Other STs‡ 2 1
  Dublin 18 11 ST10 18 11
  Others 8 5 Other STs§ 8 5
*iNTS: invasive non- typhoidal Salmonella.
†Total 8 countries: Burkina Faso, Ghana, Guinea- Bissau, Kenya, Madagascar, Senegal, South Africa and Tanzania presented in this table. No 
iNTS isolates were yielded in Sudan and Ethiopia.
‡Other sequence types of S. Enteritidis detected: 1 ST183 (isolate yielded from Ghana; age/sex unknown due to missing data) and 1 ST2107 
(from Ghana; a 22- year- old woman); both non- MDR and no antimicrobial resistant genes detected.
§Sequence types of the other NTS serovars: 1 Muenster ST321 (yielded from Ghana; age/sex/year unknown due to missing data), 1 
Poona ST308 (yielded from Ghana in 2008; age/sex unknown due to missing data), 1 Stanleyville ST339 (yielded from Ghana; age/sex/
year unknown due to missing data), 1 Virchow ST359 (from Ghana; age/sex/year unknown due to missing data), 3 Choleraesui ST145 (two 
isolates yielded from 1- year- old female infants in 2010 and 2011 and 1 from a 3- year- old female infant in 2012; all from Guinea- Bissau), 1 
unknown ST2533 from Tanzania.
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informed the study design to address issues regarding 
healthcare access and practices. Local communities and 
patients acted as communicators in the local communi-
ties to encourage people to attend healthcare facilities 
when symptomatic. Data from the studies have been 
provided to study sites to inform the local community 
and patients of the study findings.
Bacterial isolates and antimicrobial susceptibility testing
Blood specimens were inoculated into an aerobic blood 
culture bottle and incubated in systems with auto-
mated growth detection (BACTEC Peds Plus Medium/
BACTECT Plus Aerobic- F, BACTEC, Becton- Dickinson, 
New Jersey; or BacT/ALERT PF Paediatric FAN/BacT/
ALERT FA FAN Aerobic, bioMerieux, Marcy l’Etoile, 
France). Blood cultures with bacterial growth were sub- 
cultured on blood and chocolate agar (Oxoid, Basing-
stoke, UK), and biochemical tests were conducted 
(API 20E; bioMerieux) to identify suspected Salmo-
nella isolates.30 Antimicrobial susceptibility testing was 
performed using agar diffusion tests according to the 
Clinical Laboratory and Standards Institute guidelines.30
Data sources and bacterial isolates
A total of 166 iNTS isolates were used for this investiga-
tion, which comprised 94 iNTS isolates from the TSAP 
study, an additional 23 iNTS isolates obtained from 
outside predefined TSAP study catchment areas and 49 
iNTS isolates from other studies. In order to place these 
S. Typhimurium and S. Enteritidis isolates into a global 
phylogenetic context, the existing datasets were incor-
porated: 147 iNTS serotype Typhimurium ST313 isolates 
from seven countries (Malawi, Kenya, Mozambique, 
Uganda, DRC, Nigeria and Mali),11 Nigeria and DRC,12 
Malawi,28 Kenya,14 Malawi32 and 594 iNTS serotype Ente-
ritidis ST11 isolates (selected from Feasey et al13; online 
supplemental table 1).
Whole genome sequencing
Genomic DNA was extracted from all Salmonella isolates 
using the Wizard Genomic DNA Extraction Kit (Promega, 
Wisconsin, USA). Two micrograms of genomic DNA 
from each organism was subjected to indexed- tagged 
pair- end sequencing on an Illumina Hiseq 2000 platform 
(Illumina, CA, USA) at the Wellcome Sanger Institute to 
generate 100 bp paired- end reads. Data quality control 
was performed using in- house pipelines. Raw sequence 
data are available in the European Nucleotide Archive 
(Project number: ERP009684, ERP010763, ERP013866) 
(online supplemental table 2).
Single nucleotide polymorphism (SNP) calling and analyses
Raw Illumina reads were used to create multiple assem-
blies using Velvet V.1.233 with parameters optimised using 
VelvetOptimiser V.2.2.5,34 35 and automated annotation 
was performed using PROKKA V.1.5.36 Roary37 was used 
to define the pan genome of 166 iNTS isolates with blastp 
percentage identity of 99% and a core definition of 99%. 
In total, 3450 core genes were identified (genes that 
were present in ≥99% strains) and 86 765 SNP sites were 
extracted from the core gene alignment using SNP- sites 
V.2.1.3.35
For S. Typhimurium ST313, raw Illumina reads of 99 
isolates from this study and 147 S. Typhimurium ST313 
from previous studies11 12 29 33 38 were mapped to the refer-
ence sequence of S. Typhimurium strain SL1344 (accession: 
FQ312003.1), using SMALT V.0.7.4 (http://www. sanger. 
ac. uk/ resources/ software/ smalt/). Candidate SNPs were 
called against the reference sequence using SAMtools38 
and filtered with a minimum mapping quality of 30 and 
minimum consensus base agreement of 75%. The allele at 
each locus in each isolate was determined by reference to the 
consensus base in that genome using SAMtools mpileup and 
removing low confidence alleles with consensus base quality 
≤20, read depth ≤5 or a heterozygous base call. The repeat 
finding program in NUCmer V.3.139 was used to identify 
exact repetitive regions of ≥20 bp in length in the reference 
genome and SNPs called in these regions were excluded. 
SNPs called in phage sequences and recombinant regions 
identified using Gubbins40 were further removed, resulting 
in a final set of 1960 chromosomal SNPs. The identification 
of SNPs for S. Enteritidis ST11 was performed following the 
same procedure as S. Typhimurium ST313. Briefly, the raw 
Illumina reads of 28 S. Enteritidis ST11 isolates from this 
study and 594 additional isolates from a global collection13 
were mapped to the reference sequence of S. Enteritidis 
strain P125109 (accession: NC_011294.1), using SMALT 
Figure 1 Geographical distribution of iNTS genotypes and 
serotypes in the sampled countries in sub- Saharan Africa. 
Different colours in the pie charts correspond to different 
sequence types and serovars of iNTS isolates in our study 
sites. The size of the pie charts corresponds to the numbers 
of isolates in each country. Countries coloured in grey 
highlight the study sites, while red and white circles indicate 
countries with and without MDR iNTS isolates, respectively.
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followed by SNP calling and filtering as described previously, 
resulting in a final set of 25 121 SNPs.
Phylogenetic analyses
A maximum likelihood (ML) phylogenetic tree was 
constructed from the 86 765 SNP alignment of all 166 
iNTS isolates using RAxML V.8.2.8 with a generalised time- 
reversible model and a Gamma distribution to model the 
site- specific rate variation (GTRGAMMA).41 Clade support 
for this tree was assessed through a bootstrap analysis with 
100 pseudo- replicates. To investigate the molecular epidemi-
ology of the S. Typhimurium ST313 and S. Enteritidis ST11 
isolates sequenced here in a global context, a ML tree was 
inferred from an alignment of 1960 SNPs for 246 S. Typhi-
murium ST313 (99 from this study and 147 from previous 
studies11 12 29 33 38) and an alignment of 25 121 SNPs for 622 
S. Enteritidis ST11 isolates (28 from this study and 594 from 
a global collection13), using RAxML with GTRGAMMA 
model. Support for these phylogenetic trees was assessed 
through a 100 bootstrap pseudo- analysis. Tree annotation 
was visualised using ITOL.42
Antimicrobial resistance gene and plasmid analyses
From raw Illumina reads, Short Read Sequence Typing- 
SRST243 was used to identify acquired AMR genes and their 
precise alleles using the ARG- Annot database,44 as well as 
plasmid replicons using the PlasmidFinder database.45 Multi-
locus sequence typing (MLST) of all iNTS isolates was also 
determined using SRST2 together with the MLST database 
for Salmonella enterica downloaded from pubMLST (https:// 
pubmlst. org/ organisms/ salmonella- spp).46 Salmonella sero-
types were identified using conventional serology as well 
as MLST- based approach47 and SeqSero (genome- based 
approach)48; the final interpretation followed a consensus 
of MLST and SeqSero. Bandage49 was used to investigate the 
assembled contigs carrying the AMR cassettes. Mutations in 
fluoroquinolone resistance genes (gyrA, gyrB, parC, parE) 
were identified using SeaView.50
Incidence analyses of MDR iNTS disease
Incidence rates of MDR iNTS were estimated for study sites 
in Burkina Faso, Ghana, Guinea- Bissau, Kenya and Senegal. 
Statistical methodology used previously to calculate the 





MDR iNTS isolates per 
serovar*
MDR iNTS serovar per country
(%, number)
MDR iNTS per genotype
(%, number)
Typhimurium (n=110) 85% (94/110) Burkina Faso (50, 6/12) ST313 (95, 94/99)
Ghana (64, 85/133) ST19 (0, 0/11)
Guinea- Bissau (22, 2/9)   
Kenya (100, 1/1)   
Enteritidis (n=30) 23% (7/30) Burkina Faso (33, 4/12) ST11 (25, 7/28)
Ghana (2, 2/133)   
Senegal (50, 1/2)   
Dublin (n=18) 6% (1/18) Ghana (1, 1/133) ST10 (6, 1/18)
Others (n=8) 0% (0/8) n.a. n.a.
Countries
(number of iNTS) Number of MDR iNTS (n=102) % of MDR iNTS gyrA
Burkina Faso (n=12) 10 10/12 (83) 0
Ghana (n=133) 88 88/133 (66) S83Y (ST313, 2 isolates)
D87G (ST11, 6 isolates)
D87Y (ST11, 2 isolates)
D87N (ST11, 3 isolates)
Guinea- Bissau (n=9) 2 2/9 (22) 0
Kenya (n=1) 1 1/1 (100) 0
Senegal (n=2) 1 1/2 (50) 0
*Multidrug resistance (MDR) definition used for the analysis presence of resistant genes for at least one agent in all three antimicrobial 
categories listed below (detected in this study): ampicillin (blaCTX_M, blaOXA, blaTEM), chloramphenicol (catA1), trimethoprim–
sulfamethoxazole (sulfonamide (sul1, sul2) and trimethoprim (dfrA, dfrA1, dfrA14, dfrA8)).
†Refer to table 1 for the number of iNTS isolates per country used as a denominator to calculate the % of MDR per country in this table.
‡The 2 MDR iNTS isolates with gyrA mutation (fluoroquinolone resistance) were yielded from a 1- year- old female infant and a 10- month- old 
female infant in Agogo in 2011 (TSAP: Typhoid Fever Surveillance Program).
§Spv locus was detected in all MDR iNTS isolates.
n.a., not available.
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incidence of S. Typhi and iNTS disease in the TSAP study 
was used to calculate MDR iNTS incidence.7 30 51 Demo-
graphic data from Health and Demographic Surveillance 
System (HDSS) sites were used to estimate population 
denominators where available. In non- HDSS sites, health- 
seeking behaviour as reported by randomly administered 
healthcare utilisation surveys were used to estimate popula-
tion denominators for each study site. Crude incidence rates 
were adjusted to account for the proportion of surveyed 
individuals who reported seeking care for a febrile episode 
at a study facility to yield adjusted incidence rates. Adjusted 
incidence rates of MDR iNTS cases per 100 000 per person- 
years- of- observation (PYO) were estimated with 95% CIs 
using these adjustment factors and crude MDR iNTS case 
numbers. The previously established multi- country database 
(Microsoft Visual FoxPro 7.0, Redmond, Washington) for 
TSAP was used for the countries with MDR iNTS isolates.
RESULTS
Geographical distribution of iNTS serotypes and sequence 
types
The majority (66%; 110/166) of iNTS organisms in the 
sampled sub- Saharan African countries were S. Typhi-
murium, of which 90% (99/110) were ST313 and 10% 
(11/110) were ST19. S. Enteritidis accounted for 18% 
(30/166) of the isolates, composed of ST11 (93.3%; 
28/30), ST183 (3.3%; 1/30) and ST2107 (3.3%; 1/30). 
S. Dublin (ST10) comprised a further 11% (18/166) of 
isolates. Several other serotype STs, including S. Chol-
eraesuis ST145 (3/166), S. Muenster ST321 (1/166), 
S. Poona ST308 (1/166), S. Stanleyville ST339 (1/166) 
and S. Virchow ST359 (1/166), were also identified. S. 
Typhimurium ST313 was mostly limited to West Africa 
(table 1), whereas S. Enteritidis ST11 appeared to be 
pervasive in both West and Southern Africa. S. Dublin 
ST10 was identified in West Africa and S. Typhimurium 
ST19 was distributed across the continent.
Overall, 61% (102/166) of the iNTS organisms 
described here were MDR. These were isolated in Burkina 
Faso (83%; 10/12), Ghana (66%, 88/133), Guinea- Bissau 
(22%; 2/9), Kenya (100%; 1/1) and Senegal (50%; 1/2). 
S. Typhimurium exhibited the highest prevalence of 
MDR (85%; 94/110); 95% (94/99) of the ST313 isolates 
were MDR. In total, 23% (7/30) of S. Enteritidis and 6% 
(1/18) S. Dublin organisms were MDR; none of the S. 
Typhimurium ST19 were MDR (figure 1, table 2).
Phylogenetics and AMR of iNTS
A phylogenetic reconstruction of all iNTS isolates showed 
that the three major serovar STs—S. Typhimurium (ST313), 
S. Enteritidis (ST11) and S. Dublin (ST10)—formed inde-
pendent clusters with dissimilar AMR gene profiles (figure 2). 
Almost all of the MDR S. Typhimurium ST313 (95%; 94/99) 
carried the Tn21 transposon- associated MDR- loci (sulII- strAB- 
dfrA1- aadA1- sulI- cat- blaTEM) on an IncF virulence- resistance 
plasmid (pSLT- BT).11 A single MDR S. Typhimurium ST313 
from Kenya additionally carried two copies of blaCTX- M-15, 
conferring resistance to third- generation cephalosporins. 
One copy of blaCTX- M-15 was located on the 300 kb IncHI2 
plasmid, pKST313 (accession number: LN794248), and 
Figure 2 Antimicrobial resistance genes and plasmids associated with iNTS isolates circulating in sampled sub- Saharan 
African countries. Midpoint- rooted maximum likelihood phylogenetic tree based on the core genes of iNTS isolates sequenced 
in this study and their corresponding metadata. The first column shows the sequence types in different colours. The second 
column corresponds to the countries where our iNTS isolates were detected. The remaining columns exhibit a heatmap of 
detected AMR genes and plasmid replicons. The tree scale bar indicates the number of substitutions per variable site.
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the other on the chromosome disrupting the ompD locus. 
Reduced susceptibility to fluoroquinolones in S. Typhimu-
rium ST313 was uncommon, with 2% (2/99) of Ghanaian 
ST313 isolates possessing a single mutation (S87Y) in gyrA 
(table 2).
The majority of S. Enteritidis ST11 (19/28; 68%) harboured 
the typical IncF virulence plasmid (60 kb), which was 
comparable with pSENV (accession number NC_019120.1, 
coverage 100%, identity 99%). The remaining S. Enterit-
idis ST11 (9/28; 32%) harboured a novel IncI1 virulence- 
resistance plasmid (pSEP, accession number: ERP121368) of 
approximately 68 kb (figure 3), of which 7/28 (25%) isolates 
(4 from Burkina Faso, 2 from Ghana, 1 from Senegal) 
carried the MDR- encoding Tn21- like transposon (sulII- strAB- 
tetB- dfrA1- sulI- cat- blaTEM), and 2/28 (7.1%) isolates carried 
a different AMR cassette (TnpA- sulII- strAB- blaTEM- Tn3). The 
novel IncI plasmid exhibited 60% homology to pSENV but 
did not harbour the IncF replicon, the pefBACD fimbriae- 
encoding operon, or the virulence- associated genes srgA and 
rck (figure 3). In addition, two non- MDR Ghanaian S. Enterit-
idis ST11 possessed an AMR cassette (sul2- strAB- tetA) carried 
on a small (11 kb) non- conjugative IncQ plasmid conferring 
resistance against sulfonamides, streptomycin and tetracy-
clines. This IncQ plasmid exhibited a similar genetic struc-
ture to pSTU288-2 from S. Typhimurium (accession number 
CP004059.1, coverage 98%, identity 99%). Two further 
non- MDR Ghanaian isolates carried a Tn21- mediated AMR 
cassette (sulII- strAB- dfrA1- aadA1- sulI- cat) on the virulence 
plasmid, and a single non- MDR isolate from Madagascar 
carried a blaTEM Tn3 integrated into the virulence plasmid. 
Reduced susceptibility to fluoroquinolones was predicted by 
the sequences in 39% (11/28) of the S. Enteritidis- ST11, all 
of which originated from Ghana and displayed a variety of 
gyrA mutations (D87G: 6 isolates, D87N: 3 isolates, D87Y: 2 
isolates) (table 2).
Phylogenetics of S. Typhimurium ST313 and S. Enteritidis 
ST11 isolates in global context
To investigate the population structures of S. Typhimu-
rium ST313 and S. Enteritidis ST11 in a broader context, 
we constructed global phylogenies. All S. Typhimu-
rium ST313 isolates from our study fell into lineage II 
(figure 4A). The single Kenyan ST313 isolate carrying two 
copies of blaCTX- M-15 was part of the previously described 
clonal expansion of MDR ceftriaxone- resistant ST313 
sub- lineage.14 Notably, the Ghanaian ST313 isolates 
did not form a single cluster, but were associated with 
multiple clusters from Mali, Burkina Faso and Nigeria, 
indicating multiple introduction events (figure 4A).
A detailed phylogenetic investigation of S. Enteritidis 
ST11 demonstrated that 11/28 (40%) (Ghana: 5, Burkina 
Faso: 4, Senegal: 1, Guinea Bissau: 1) isolates fell into the 
Figure 3 Novel IncI1 virulence- resistance plasmid (pSEP) in an S. Enteritidis ST11 isolate. Plasmid comparison analyses 
between the novel virulence- resistance IncI1 plasmid pSEP (bottom) and the reference virulence IncF plasmid pSENV (top). The 
grey blocks show the BLASTn comparison between the two plasmids using the bl2seq feature from the web- based BLAST. 
Some annotations are added for both plasmids. Red- coloured arrows are genes associated with virulence and AMR. Blue- 
coloured arrows are genes associated with conjugation. Grey- coloured arrows correspond to plasmid replication and stability. 
Green- coloured genes are associated with transposon elements.
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West African clade.13 The ST11 organisms within this West 
African clade displayed either MDR (seven isolates) or 
other non- MDR AMR phenotypes (two isolates). We found 
evidence that some Ghanaian isolates within this clade clus-
tered alongside organisms from Burkina Faso and Mali, 
again suggesting international transmission. In addition, 
13/28 (46%) of the S. Enteritidis ST11 (Ghana: 11, Mada-
gascar: 1, South Africa: 1) belonged to the Global epidemic 
clade.13 These isolates had phylogenetic links with their 
country- specific clusters, with the exception of two Ghanaian 
isolates that clustered with organisms from neighbouring 
Cameroon and Senegal. Lastly, 4/28 (14%) (2 from Ghana, 
2 from Madagascar) of the ST11 isolates grouped within the 
outlier cluster (figure 4B).
Incidence of MDR iNTS disease in sub-Saharan Africa
We calculated the age- stratified incidence rates of MDR 
iNTS in previously described study catchment areas in 
Burkina Faso, Ghana, Guinea- Bissau and Kenya (table 3). 
The adjusted incidence of MDR iNTS disease exceeded 
100/100 000 PYO in children <15 years of age in all West 
African countries: Burkina Faso (Nioko II, 274/100 000 
PYO, 95% CI 185 to 406; Polesgo, 255/100 000 PYO, 95% 
CI 138 to 470), Ghana (Asante Akim North: Ghana- AAN, 
414/100 000, 95% CI 333 to 515) and Guinea- Bissau 
(Bandim, 105/100 000, 95% CI 69 to 161). Among chil-
dren <15 years, younger children (<2–4 years) exhibited the 
highest MDR iNTS incidence rates in both sites in Burkina 
Faso: 753/100 000 PYO (95% CI 460 to 1233) in Nioko II 
and 630/100 000 PYO (95% CI 288 to 1380) in Polesgo. In 
both settings in Burkina Faso, the incidence of MDR iNTS 
disease in the infant age group was slightly lower than in the 
group aged 2–4 years, but children <5 years old exhibited a 
high burden of MDR iNTS disease. In Ghana- AAN, infants 
aged <2 years had the highest incidence of MDR iNTS 
disease (1435/100 000; 95% CI 1110 to 1854) followed by 
children aged between 2 and 5 years (747/100 000; 95% 
CI 491 to 1135). Similarly, in Guinea- Bissau, infants <2 years 
old exhibited the highest incidence of MDR iNTS disease 
(291/100 000; 95% CI 176 to 482). The incidence rate of 
MDR iNTS in older age groups (≥15 years) was relatively 
Figure 4 Phylogenetics of S. Typhimurium ST313 lineage II and S. Enteritidis ST11 in sub- Saharan Africa. (A) Maximum 
likelihood phylogenetic tree of S. Typhimurium- ST313 lineage II isolates from this study in the context of the sub- Saharan 
African continent; lineage I was pruned to enhance the visualisation of the tree. Red circles at the terminal leaves correspond 
to our study isolates. The first column shows different colour- coded countries from where all analysed isolates originate. The 
second column shows MDR and non- MDR isolates in red and grey, respectively. (B) Maximum likelihood phylogenetic tree of 
our S. Enteritidis- ST11 isolates in the global context of S. Enteritidis. Red circles at the terminal leaves correspond to our study 
isolates. The first and second columns show regions and resistant phenotypes in different colours. The tree scale bar indicates 
the number of substitutions per variable site.
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low, ranging between 0 (Guinea- Bissau) to 11 (Kenya) and 
54 (Burkina Faso) per 100 000 PYO.
DISCUSSION
Our study shows that MDR iNTS is highly prevalent in 
several sub- Saharan African countries. Specifically, we 
found that MDR S. Typhimurium ST313 is the most 
common cause of iNTS disease, but that other iNTS 
serovars, principally S. Enteritidis ST11 and S. Dublin 
ST10 in West Africa, also constitute a major proportion 
of the disease burden.52 53 Our phylogenetic analyses 
provide further evidence for the regional transmission 
of two MDR serovars/STs (S. Typhimurium ST313 and 
S. Enteritidis ST11) between Ghana and neighbouring 
countries Burkina Faso, Nigeria, Mali and Senegal. These 
transmission events highlight the need for intensified 
AMR surveillance, the coordination of AMR reporting, 
and sustained public health control measures between 
these and other African countries.
We calculated a particularly high incidence of MDR iNTS 
disease in the West African countries of Burkina Faso, Ghana 
(<5 years) and Guinea- Bissau (<2 years). The incidence rates 
Table 4 All iNTS organisms analysed







Ghana§ Guinea- Bissau Kenya Madagascar Senegal South 
Africa
Tanzania
12 133 9 1 4 2 1 4
4 (Polesgo)
8 (Nioko II)

























Published iNTS Typhimurium ST313 Lineage II isolates (N=102)**
  DRC†† Kenya Malawi Mali Mozambique Nigeria Uganda
  8 9 55 18 3 6 3
Published iNTS Enteritidis ST11 isolates (N=677)‡‡




Southern Africa Northern 
Africa
Rest of the 
World
  90 262 131 11 183
*Total 945 iNTS organisms were analysed in this manuscript: 166 iNTS isolates from the TSAP and other Ghana projects; sequenced and 
published 102 iNTS serovar Typhimurium ST313 Lineage II isolates from seven countries (DRC/Kenya/Malawi/Mali/Mozambique/Nigeria/
Uganda); and sequenced and published 594 (out of 677) iNTS serovar Enteritidis ST11 isolates (see online appendices for the metadata).
†TSAP: Typhoid Fever Surveillance Program.7 30 Of the 10 countries under the TSAP, no iNTS was found in Sudan and Ethiopia. 4 and 1 
iNTS strains were identified from Madagascar and South Africa, respectively, through the whole genome sequencing; no iNTS isolates 
were reported from Madagascar and South Africa based on the blood culture result. Few analysed iNTS isolates, which may have been 
detected outside the strictly predefined surveillance catchment area, are considered for the bacterial genomic analysis, but excluded from 
the incidence estimation of the multidrug resistant iNTS in respective sites in table 4. The 166 iNTS isolates included for the final genomic 
analyses are based on the screening of whole genome sequenced results.
‡Non- TSAP projects in Ghana include the ‘Febrile Illnesses Surveillance in Africa (FISA)’, ‘Typhoid Surveillance in Africa (TYSA)’ and 
‘IsolateAgogo’ conducted in Agogo.
§Ghana: 133 iNTS isolates analysed in this manuscript include 84 iNTS detected through the TSAP in Asante Akim North and 49 iNTS from 
several non- TSAP projects conducted in Agogo.
¶49 (Agogo): 49 iNTS isolates detected from various non- TSAP projects in Agogo, Ghana as listed in this table.
**Total 102 iNTS Typhimurium ST313 Lineage II isolates, which had been collected in seven countries in sub- Saharan Africa and whole 
genome sequenced, were published and raw sequence data accessible at the Wellcome Trust Sanger Institute. Global collection of S. 
Typhimurium and additional S. Typhimurium from Malawi, Kenya, Mozambique, Uganda, DRC, Nigeria and Mali11; Nigeria and DRC12; 
Malawi28; Kenya (Kariuki et al 2015b); Malawi.32 Whole genome sequenced 166 iNTS isolates from TSAP and non- TSAP projects in Ghana 
listed in this table included 99 iNTS Typhimurium ST313 Lineage II . This 99 ST313 Lineage II was combined with the raw sequence data of 
102 ST313 Lineage II published isolates listed in this footnote. Total 201 ST313 Lineage II isolates were further analysed.
††DRC: Democratic Republic of Congo.
‡‡Raw sequence data of the published global collection of 594/677 S. Enteritidis isolated from human and animal samples (Feasey et al 
2016) were accessible at the Wellcome Trust Sanger Institute. The associated metadata were publicly available online. These samples 
were collected and whole genome sequenced across the African continent and the world: Western Africa: Benin, Cameroon, Chad, Gabon, 
Guinea, Ivory Coast, Mali, Niger and Senegal. Central and Eastern Africa: Central African Republic, Comoros, Congo, Djibouti, Ethiopia, 
HPA, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda and Uganda. Southern Africa: Republic of South Africa. Northern 
Africa: Algeria, Egypt, Mauritania, Morocco and Tunisia. Rest of the World: Angola, Argentina, Colombia, Germany, Italy, Japan, PTG, Ratin- 
manufactured rat poison, Slovakia, Spain, Thailand, UK, Uruguay, USA and unknown.
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of MDR iNTS disease presented here generally correspond 
with the incidence of iNTS disease in other African coun-
tries.7 Effective antimicrobial therapy is an essential compo-
nent of iNTS management; however, the effectiveness of 
first- line treatments has been diminished due to the emer-
gence and spread of MDR and XDR NTS strains.13 29 54 Our 
data also depict the emergence of reduced fluoroquinolones 
susceptibility in both MDR ST313 and ST11 in Ghana, as 
well as the circulation of a ceftriaxone- resistant ST313 sub- 
lineage in Kenya. Invasive Salmonella with reduced suscep-
tibility to ciprofloxacin have been reported in Burkina 
Faso,7 Ghana,7 21 Nigeria,55 Senegal,56 Mozambique,23 the 
Congo,29 57 Kenya58 and South Africa.59 This increasing trend 
in resistance against clinically important classes of antimi-
crobials in differing iNTS serovars across Africa is of major 
concern.14 The growing use of ceftriaxone and ciprofloxacin 
for the treatment of febrile illnesses in Africa may lead to an 
increase in of MDR and XDR pathogens in this continent, 
which has already been observed across Asia in the last two 
decades.
Several limitations should be considered in interpreting 
and generalising these data beyond our study sites. While we 
are able to illustrate the magnitude of the problem of MDR 
iNTS in West Africa, there are relatively few genomic data 
points available from countries in East and Southern Africa. 
Previous studies showed high prevalence of MDR iNTS 
disease in Kenya27 58 and a recent meta- analysis suggested that 
MDR iNTS has emerged across four regions of sub- Saharan 
Africa.60 The generation and analysis of additional epidemi-
ological and genomic iNTS data in Eastern/Southern Africa 
would help facilitate comparison of incidence rates and 
AMR profiles of iNTS- associated organisms between African 
regions. Further, the estimated incidence rates of MDR iNTS 
disease in our study should be interpreted with caution as the 
number of cases in some countries were relatively small. In 
parallel, the original study design may also have led to some 
underestimation of iNTS burden, as afebrile patients with 
other clinical symptoms associated with iNTS disease were 
not enrolled. As a result, the true incidence of MDR iNTS 
disease in some settings need to be further monitored with 
more systematic disease surveillance.
Despite the identified limitations, our study provides 
enhanced insights into the population structure and 
transmission dynamics of major MDR iNTS serovars 
in sub- Saharan Africa and identified countries with a 
high burden of MDR iNTS. There is an urgent need to 
expand clinical and genomic surveillance for pathogens 
causing bloodstream infections across continental Africa 
to improve our understanding of disease incidence and 
to monitor AMR trends. Such data can better inform 
antimicrobial stewardship to extend the life of existing 
antimicrobial therapies and prioritisation of preventa-
tive interventions including vaccines. The development 
and deployment of a safe, low- cost, highly efficacious 
multivalent vaccine should be prioritised for the manage-
ment and prevention of iNTS disease in Africa, partic-
ularly in countries with high prevalence of MDR iNTS 
infections, as well as HIV, malaria and malnutrition.61 62 
Meanwhile, further investigations of household transmis-
sion dynamics and human and non- human reservoirs of 
infection are warranted to inform better iNTS control 
measures and, ultimately, optimal programmatic use of 
future vaccines.
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